Skip to main content

Advertisement

Table 3 Neutralizing antibody titers of mice injected twice with the vaccine and virus titers in the lungs after challenge

From: Potency of a vaccine prepared from A/swine/Hokkaido/2/1981 (H1N1) against A/Narita/1/2009 (H1N1) pandemic influenza virus strain

Vaccine NT titer to Virus titer in lungs, mean log PFU/g ±Sea
Strain Protein, μg Formulation Narita/09 Sw/Hok/81  
PBS - - <10, <10, <10, <10, <10 <10, <10, <10, <10, <10 4.4±0.08
Sw/Hok/81 4.0 ES <10, <10, <10, <10, <10 20, 40, 80, 160, 160 4.4±0.07
  20 ES <10, <10, <10, <10, <10 80, 80, 160, 160, 160 4.2±0.19
  100 ES <10, <10, <10, <10, <10 80, 80, 160, 320, 310 3.9±0.14*
Sw/Hok/81 4.0 WV <10, <10, <10, <10, <10 160, 320, 320, 640, 640 4.2±0.11
  20 WV <10, <10, <10, <10, <10 160, 320, 640, 640, 640 3.9±0.28
  100 WV <10, 10, 40, 40, 160 160, 320, 640, 640, 640 2.9±0.30**
  1. Mice were injected twice with each vaccine subcutaneously with a 2-week interval. Serum samples were collected 2 weeks after the final immunization.
  2. The animals were challenged by intranasal administration of 106.0 PFU of A/Narita/09.
  3. At 3 days after challenge, lungs samples were collected and virus titers were measured. ES: ether split vaccine, WV: whole inactivated vaccine
  4. a: Data are for 5 mice.
  5. *: P<0.05, vs. virus titers in PBS group.
  6. **: P<0.01, vs. virus titers in PBS group.